BCAX
Price
$17.61
Change
-$0.30 (-1.68%)
Updated
Oct 22 closing price
Capitalization
1.17B
18 days until earnings call
Intraday BUY SELL Signals
TARA
Price
$2.44
Change
-$0.06 (-2.40%)
Updated
Oct 22 closing price
Capitalization
144.19M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAX vs TARA

BCAX vs TARA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BCAX vs. TARA commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAX is a StrongBuy and TARA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCAX with price predictions
Oct 22, 2026

BCAX's RSI Indicator recovers from oversold territory

The RSI Oscillator for BCAX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 6 similar instances when the indicator left oversold territory. In 6 of the 6 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BCAX as a result. In 24 of 34 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for BCAX just turned positive on October 13, 2026. Looking at past instances where BCAX's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.

Following a +9.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAX advanced for three days, in 99 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

BCAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 18 of 18 cases where BCAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for BCAX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.486) is normal, around the industry mean (2.973). P/E Ratio (-5.736) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. BCAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TARA with price predictions
Oct 22, 2026

TARA's RSI Indicator ascends from oversold territory

The RSI Indicator for TARA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where TARA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for TARA just turned positive on October 21, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.

Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in 174 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TARA as a result. In 73 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for TARA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.894) is normal, around the industry mean (2.973). P/E Ratio (-1.794) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
TARA: Fundamental Ratings
TARA
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
13
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCAXTARA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (BCAX: $17.91 vs. TARA: $2.50)
Brand notoriety: BCAX and TARA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAX: 100% vs. TARA: 89%
Market capitalization -- BCAX: $1.17B vs. TARA: $144.19M
BCAX [@Biotechnology] is valued at $1.17B. TARA’s [@Biotechnology] market capitalization is $144.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAX’s FA Score shows that 1 FA rating(s) are green while TARA’s FA Score has 1 green FA rating(s).

  • BCAX’s FA Score: 1 green, 4 red.
  • TARA’s FA Score: 1 green, 4 red.
According to our system of comparison, TARA is a better buy in the long-term than BCAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAX’s TA Score shows that 5 TA indicator(s) are bullish while TARA’s TA Score has 5 bullish TA indicator(s).

  • BCAX’s TA Score: 5 bullish, 3 bearish.
  • TARA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both BCAX and TARA are a good buy in the short-term.

Price Growth

BCAX (@Biotechnology) experienced а +3.29% price change this week, while TARA (@Biotechnology) price change was +0.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

BCAX is expected to report earnings on Nov 09, 2026.

TARA is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BCAX
Daily Signal:
Gain/Loss:
TARA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

BCAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with STOK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then STOK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAX
1D Price
Change %
BCAX100%
-1.68%
STOK - BCAX
47%
Loosely correlated
+0.08%
CLDX - BCAX
47%
Loosely correlated
-1.36%
RCUS - BCAX
44%
Loosely correlated
+1.36%
RAPP - BCAX
43%
Loosely correlated
+5.87%
CGON - BCAX
43%
Loosely correlated
+0.48%
More

TARA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARA has been loosely correlated with AMLX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TARA jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARA
1D Price
Change %
TARA100%
-2.40%
AMLX - TARA
40%
Loosely correlated
-1.58%
BCAX - TARA
39%
Loosely correlated
-1.68%
ARVN - TARA
38%
Loosely correlated
+2.18%
CGON - TARA
36%
Loosely correlated
+0.48%
IMNM - TARA
36%
Loosely correlated
+1.44%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VNM17.060.08
+0.47%
VanEck Vietnam ETF (VNM)
SCYB25.150.06
+0.24%
Schwab High Yield Bond ETF (SCYB)
TINS28.04N/A
N/A
Templeton International Insights ETF (TINS)
IHY20.71-0.03
-0.16%
VanEck International High Yield Bond ETF (IHY)
XJUN45.44-0.22
-0.48%
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - June (XJUN)